Acute Lung Injury Market Report 2026

Acute Lung Injury Market Overview

• Acute Lung Injury market size has reached to $2.59 billion in 2025 • Expected to grow to $3.19 billion in 2030 at a compound annual growth rate (CAGR) of 4.2% • Growth Driver: Rising Prevalence Of Respiratory Diseases Is Driving The Growth Of The Market • Market Trend: Advancements In Acute Lung Injury Enhanced Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Acute Lung Injury Market?

Acute lung injury (ALI) is a severe condition characterized by widespread inflammation and damage to the lungs, leading to impaired oxygen exchange. It is often triggered by direct factors such as pneumonia or trauma, or indirect causes such as sepsis or pancreatitis. ALI results in symptoms such as shortness of breath, low oxygen levels, and respiratory distress. The main types of acute lung injury are direct injury and indirect injury. A direct injury refers to harm or damage that occurs as a direct result of an action, event, or incident. Therapy options include mechanical ventilation, pharmacotherapy, fluid management, and others and are utilized by various end users, including hospitals, clinics, and others.

What Is The Acute Lung Injury Market Growth Forecast?

The acute lung injury market size is expected to see steady growth in the next few years. It will grow to $3.19 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to development of novel pharmacotherapies for ALI, increasing integration of ai in patient monitoring, expansion of intensive care units globally, rising adoption of personalized treatment plans, advancement in minimally invasive ventilation technologies. Major trends in the forecast period include rising incidence of acute lung injury cases globally, increased adoption of mechanical ventilation technologies, growing use of pharmacotherapy and fluid management, focus on early diagnosis and monitoring tools, expansion of hospital-based critical care facilities.

Global Acute Lung Injury Market Segmentation

1) By Injury Type: Direct Injury, Indirect Injury 2) By Therapy: Mechanical Ventilation, Pharmacotherapy, Fluid Management, Other Therapies 3) By End User: Hospitals, Clinics, Other End Users Subsegments: 1) By Direct Injury: Trauma-Induced Acute Lung Injury, Aspiration Pneumonitis, Pneumonia-Related Acute Lung Injury, Inhalation Injury 2) By Indirect Injury: Sepsis-Related Acute Lung Injury, Shock-Induced Acute Lung Injury, Acute Lung Injury Due To Blood Transfusion, Acute Lung Injury Associated With Pancreatitis

What Is The Driver Of The Acute Lung Injury Market?

The rising prevalence of respiratory diseases is expected to propel the growth of the acute lung injury market going forward. Respiratory diseases refer to a group of conditions that affect the lungs and other parts of the respiratory system, leading to difficulty in breathing and impaired lung function. The rising prevalence of respiratory diseases can be due to increased air pollution, smoking, sedentary lifestyles, aging populations, and the impact of viral infections. Respiratory diseases, such as pneumonia, cause acute lung injury by triggering severe inflammation and damaging the alveoli, leading to impaired gas exchange and respiratory distress. For instance, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, in 2023, Australia recorded a total of 474 asthma-related deaths, comprising 325 females and 149 males. This figure is almost identical to the 473 asthma-related deaths reported in 2022, highlighting a consistent trend in asthma mortality over the two years. Therefore, the rising prevalence of respiratory diseases is driving the growth of the acute lung injury industry.

Key Players In The Global Acute Lung Injury Market

Major companies operating in the acute lung injury market are Medtronic plc, Baxter International Inc., GE Healthcare Technologies Inc., Drägerwerk AG & Co. KGaA, Getinge AB, Koninklijke Philips N.V., Hamilton Medical AG, Vyaire Medical Inc., Vapotherm Inc., GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Faron Pharmaceuticals Oy, Windtree Therapeutics Inc., Apeiron Biologics AG, ReAlta Life Sciences Inc., Vasomune Therapeutics Inc., MediciNova Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc.

Global Acute Lung Injury Market Trends and Insights

Major companies operating in the acute lung injury treatment market are focusing on developing advanced solutions, such as recombinant human plasma gelsolin (rhu-pGSN), to rebalance dysfunctional inflammation, regulate critical immune responses, and potentially improve patient outcomes in severe lung injury. Recombinant human plasma gelsolin (rhu-pGSN) is based on gelsolin, a highly conserved protein that plays a key role in controlling immune dysregulation in acute respiratory distress syndrome (ARDS). For instance, in June 2025, BioAegis Therapeutics, a US-based biotech company, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate, rhu-pGSN, for the treatment of ARDS. This therapy offers several unique benefits, including rebalancing dysfunctional inflammation without suppressing immune function, regulating critical immune responses in the lungs, and potentially improving outcomes for patients with severe inflammatory lung injury.

What Are Latest Mergers And Acquisitions In The Acute Lung Injury Market?

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Apeiron Biologics AG for $100 million. The acquisition of Apeiron enhances Ligand's portfolio by incorporating innovative therapies, especially in immunotherapy and cancer treatment. It also broadens Ligand's research and development capabilities, creating potential for new revenue opportunities and reinforcing its position in the biotech industry. Apeiron Biologics AG is an Austria-based biotechnology company actively involved in developing treatments for acute lung injury (ALI).

Regional Outlook

North America was the largest region in the acute lung injury market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Lung Injury Market?

The acute lung injury market consists of revenues earned by entities by providing services such as intensive care unit (ICU) care, mechanical ventilation, oxygen therapy, extracorporeal membrane oxygenation, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute lung injury market also includes sales of mechanical ventilators, oxygen therapy products, inhaled medications, sedation and analgesics, and diuretics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute Lung Injury Market Report 2026?

The acute lung injury market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute lung injury industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.